Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Engineered immune cells take aim at Hard-to-Treat blood cancers

NCT ID NCT07055477

First seen Sep 30, 2025 · Last updated Apr 29, 2026 · Updated 28 times

Summary

This early-phase trial tests whether a patient's own white blood cells, modified in a lab to recognize and attack a protein called CCR4 on cancer cells, can safely treat certain T-cell lymphomas that have not responded to standard therapy. About 60 adults with relapsed or refractory peripheral or cutaneous T-cell lymphoma will receive the modified cells after a short course of chemotherapy. The main goal is to check for side effects and determine a safe dose.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CUTANEOUS T-CELL LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institutes of Health Clinical Center

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.